Interactive Brokers shares jump as it secures spot in S&P 500
ROCHESTER, N.Y. - Vaccinex, Inc. (NASDAQ:VCNX), a clinical-stage biotechnology company currently trading at $0.68 per share, has presented new data at the Annual Meeting of Clinical Oncology (ASCO) on June 1, 2025, demonstrating the potential of its drug candidate, pepinemab, in treating head and neck cancer. According to InvestingPro analysis, the company appears undervalued despite its stock falling 87% over the past year. The study, led by Dr. Conor Steuer from Emory University’s Winship Cancer Center, showed that pepinemab may enhance immune responses to checkpoint therapies in the neoadjuvant setting, correlating with improved pathologic response in patients.
Pepinemab is designed to block Semaphorin 4D (SEMA4D), which plays a role in preventing immune cell infiltration in tumors and triggering inflammation in neurodegenerative diseases. The new data suggest that pepinemab treatment can induce the formation of tertiary lymphoid structures (TLS), which are associated with clinical benefits in immune checkpoint therapy.
The presentation at ASCO focused on the mechanisms by which neoadjuvant treatment with pepinemab, in combination with immune checkpoint treatments, did not increase toxicities yet enhanced TLS maturity. This correlation with improved pathologic response is particularly significant for patients with head and neck squamous cell carcinoma (HNSCC), which is often resistant to immune checkpoint therapy due to its immunologically "cold" nature. InvestingPro data shows analysts expect significant revenue growth of 236% this year, potentially driven by these promising clinical developments.
Vaccinex’s approach to treating cancer includes the combination of pepinemab with other therapies, such as KEYTRUDA® in the KEYNOTE-B84 study for recurrent or metastatic HNSCC and with BAVENCIO® in a study for metastatic pancreatic adenocarcinoma (PDAC). The company is also exploring pepinemab’s potential in neurodegenerative diseases, with promising results in Alzheimer’s Disease and Huntington’s disease.
The presentation of this data at ASCO represents a significant milestone for Vaccinex, as it continues to explore the clinical benefits of pepinemab in various indications. This research is part of the company’s broader efforts to pioneer treatments that inhibit SEMA4D for cancer and neurodegenerative diseases.
The information in this article is based on a press release statement and has not been independently verified. Vaccinex continues to conduct clinical trials to further investigate the efficacy and safety of pepinemab in various indications. For comprehensive financial analysis and additional insights about Vaccinex, including 16 more exclusive ProTips and detailed financial metrics, visit InvestingPro.
In other recent news, Vaccinex, Inc. is set to present significant data at the American Association for Cancer Research Annual Meeting, focusing on its drug candidate pepinemab and its role in enhancing immune responses in cancer therapy. Clinical trials have indicated that pepinemab, in combination with immune checkpoint inhibitors, can improve outcomes for patients with metastatic melanoma by promoting the development of tertiary lymphoid structures. This development is particularly promising for cancers like HPV-negative and PD-L1-low head and neck cancer, which typically show limited response to immunotherapies.
Additionally, Vaccinex announced the resignation of Bala S. Manian from its board of directors, as per a recent filing with the Securities and Exchange Commission. The company clarified that the resignation was not due to any disagreements over its operations or policies. Vaccinex has not yet named a successor or detailed the search process for a new director. This corporate change occurs as investors and regulators increasingly focus on board compositions. The company has not provided further information regarding this board change.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.